SS
CRNX

SBI Securities’s Crinetics Pharmaceuticals CRNX Stock Holding History

SBI Securities’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262 Hold
7
– – ﹤0.01% 3242
2026
Q1 		$254 Sell
7
-203
-97% -$9.07K ﹤0.01% 3127
2025
Q4 		$9.78K Buy
+210
New +$9.35K ﹤0.01% 1730
2025
Q1 		– Sell
-2
Closed -$102 – 4147
2024
Q4 		$102 Buy
+2
New +$112 ﹤0.01% 3449

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's CRNX Position: Q2 2026 in Review

SBI Securities held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 7 shares worth $262. The position accounts for ﹤0.01% of the portfolio, ranked #3242.

SBI Securities first reported a position in CRNX in Q4 2024 and has held it in 4 quarters since. The position peaked at $9.78K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • SBI Securities held 7 shares of Crinetics Pharmaceuticals worth $262 as of Q2 2026.
  • SBI Securities left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3242 holding.
  • SBI Securities first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • SBI Securities's Crinetics Pharmaceuticals position peaked at $9.78K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.